Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group. Schopohl J, et al. Among authors: ligueros saylan m. Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1. Pituitary. 2015. PMID: 25537481 Free PMC article. Clinical Trial.
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
Gevaert P, Saenz R, Corren J, Han JK, Mullol J, Lee SE, Ow RA, Zhao R, Howard M, Wong K, Islam L, Ligueros-Saylan M, Omachi TA, Bachert C. Gevaert P, et al. Among authors: ligueros saylan m. J Allergy Clin Immunol. 2022 Mar;149(3):957-965.e3. doi: 10.1016/j.jaci.2021.07.045. Epub 2021 Sep 14. J Allergy Clin Immunol. 2022. PMID: 34530020 Free article. Clinical Trial.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. Among authors: ligueros saylan m. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
Reply.
Gevaert P, Corren J, Mullol J, Han J, Lee SE, Ligueros-Saylan M, Wong K, Omachi TA, Bachert C. Gevaert P, et al. Among authors: ligueros saylan m. J Allergy Clin Immunol. 2021 Jan;147(1):413-414. doi: 10.1016/j.jaci.2020.09.025. Epub 2020 Nov 5. J Allergy Clin Immunol. 2021. PMID: 33160643 No abstract available.
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE. Azuma K, et al. J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. doi: 10.1210/jc.2007-1369. Epub 2007 Nov 27. J Clin Endocrinol Metab. 2008. PMID: 18042650 Clinical Trial.
Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Yuan W, Hu S, Li M, Yang L, Liu L, Zheng M, Guo Z, Song Z, Zhang C, Diao Q, Xu J, Richard A, Patwardhan M, Lyu T, Uddin A, Fogel R, Ligueros-Saylan M, Zheng J. Yuan W, et al. Among authors: ligueros saylan m. Dermatol Ther. 2022 Apr;35(4):e15303. doi: 10.1111/dth.15303. Epub 2022 Jan 17. Dermatol Ther. 2022. PMID: 34984792 Free PMC article. Clinical Trial.
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. Balas B, et al. J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. doi: 10.1210/jc.2006-1882. Epub 2007 Jan 23. J Clin Endocrinol Metab. 2007. PMID: 17244786 Clinical Trial.
42 results